An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Ocular Therapeutix™ to Present at the H.C. Wainwright 24th Annual Global Investment Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Ocular Therapeutix, Inc. (NASDAQ:OCUL) will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14, 2022, at 11:00 AM ET in New York City. The management will also host investor meetings during the conference. Interested investors can contact H.C. Wainwright to arrange meetings. A live webcast of the presentation will be available on the company's Investors website and can be replayed for 90 days. Ocular Therapeutix focuses on innovative therapies for eye diseases, including its FDA-approved product DEXTENZA®.
Positive
None.
Negative
None.
BEDFORD, Mass.--(BUSINESS WIRE)--
Ocular Therapeutix, Inc. (NASDAQ:OCUL), a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye, today announced that it will present at the H.C. Wainwright 24th Annual Global Investment Conference on Wednesday, September 14, 2022 at 11:00 AM ET at the Lotte New York Palace Hotel in New York, NY.
In addition to the presentation, the management team will host investor meetings. Investors participating in the conference who are interested in meeting with Ocular Therapeutix management should contact their H.C. Wainwright representative.
A live webcast of the presentation will be available and can be accessed by visiting the Investors section of the Company’s website at investors.ocutx.com. It will be available for replay for 90 days.
About Ocular Therapeutix, Inc.
Ocular Therapeutix, Inc. is a biopharmaceutical company focused on the formulation, development, and commercialization of innovative therapies for diseases and conditions of the eye using its proprietary bioresorbable hydrogel-based formulation technology. Ocular Therapeutix’s first commercial drug product, DEXTENZA®, is an FDA-approved corticosteroid for the treatment of ocular inflammation and pain following ophthalmic surgery and ocular itching associated with allergic conjunctivitis. Ocular Therapeutix’s earlier stage development assets include: OTX-TKI (axitinib intravitreal implant), currently in Phase 1 clinical trials for the treatment of wet AMD and other retinal diseases; OTX-TIC (travoprost intracameral implant), currently in a Phase 2 clinical trial for the treatment of primary open-angle glaucoma or ocular hypertension; and OTX-CSI (cyclosporine intracanalicular insert) for the chronic treatment of dry eye disease and OTX-DED (dexamethasone intracanalicular insert) for the short-term treatment of the signs and symptoms of dry eye disease, both of which have completed Phase 2 clinical trials. Ocular Therapeutix's first product, ReSure® Sealant, is an FDA-approved device to prevent wound leaks in corneal incisions following cataract surgery.
